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Differentiating Reversible Cerebral Vasoconstriction
SyndromeWith Subarachnoid Hemorrhage
FromOther Causes of Subarachnoid Hemorrhage
SusanneMuehlschlegel, MD, MPH; Oguzhan Kursun, MD; Mehmet A. Topcuoglu, MD; Joshua Fok, MD;
Aneesh B. Singhal, MD
IMPORTANCE Reversible cerebral vasoconstriction syndrome (RCVS) is a clinical-angiographic
syndrome characterized by recurrent thunderclap headaches and reversible segmental
multifocal cerebral artery narrowing. More than 30% of patients with RCVS develop
subarachnoid hemorrhage (SAH). Patients with RCVS with SAH (RCVS-SAH) are often
misdiagnosed as having potentially ominous conditions such as aneurysmal SAH (aSAH) or
cryptogenic “angiogram-negative” SAH (cSAH) owing to overlapping clinical and imaging
features.
OBJECTIVE To identify predictors that can distinguish RCVS-SAH from aSAH and cSAH at the
time of clinical presentation.
DESIGN Retrospective analysis of 3 patient cohorts: patients with RCVS (1998-2009),
patients with aSAH (1995-2003), and patients with cSAH (1995-2003).
SETTING Academic hospital and tertiary referral center.
PARTICIPANTS Consecutive patients with RCVS-SAH (n = 38), aSAH (n = 515), or cSAH
(n = 93) whose conditions were diagnosed using standard criteria.
MAIN OUTCOMES ANDMEASURES Multivariate logistic regression analysis was used to identify
predictors that differentiate RCVS-SAH from aSAH and cSAH.
RESULTS Predictors differentiating RCVS-SAH from aSAHwere younger age, chronic
headache disorder, prior depression, prior chronic obstructive pulmonary disease, lower
Hunt-Hess grade, lower Fisher SAH group, higher number of affected arteries, and the
presence of bilateral arterial narrowing. Predictors differentiating RCVS-SAH from cSAHwere
younger age, female sex, prior hypertension, chronic headache disorder, lower Hunt-Hess
grade, lower Fisher SAH group, and the presence of bilateral arterial narrowing.
CONCLUSIONS AND RELEVANCE We identified important clinical and imaging differences
between RCVS-SAH, aSAH, and cSAH that may be useful for improving diagnostic accuracy,
clinical management, and resource utilization.
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R ecent studies have characterized the reversiblecerebral vasoconstriction syndrome (RCVS) as aclinical-angiographic syndrome typically heralded by
acute, severe “thunderclap” headaches (TCHs) associated
with reversible segmental multifocal cerebral artery
vasoconstriction.1-5 Approximately one-third of patients
develop ischemic stroke, lobar hemorrhage, or convexal sub-
arachnoid hemorrhage (SAH). Patients with RCVS who
develop SAH (hereafter referred to as patients with RCVS-
SAH) pose a unique diagnostic dilemma. Although the TCH
is a cardinal symptom of RCVS, it is also the main presenting
symptom of a ruptured brain aneurysm (aneurysmal SAH
[aSAH]), and both conditions can be complicated by arterial
narrowing and ischemic stroke. Owing to its relatively recent
characterization, RCVS remains underrecognized, and
although it is a usually benign and self-limited condition, the
fear of missing aSAH (which can be fatal6) makes it challeng-
ing to confidently diagnose and manage RCVS-SAH, espe-
cially at patient presentation.
The decision-making processwith regard to patients pre-
senting with TCHs or SAH is complex. In addition to RCVS
and aSAH, TCHs can be a symptom of cerebral venous sinus
thrombosis, cerebral artery dissection, and intracerebral
hemorrhage.7 Neuroimaging is urgently needed for all pa-
tients with TCHs, to exclude potentially life-threatening con-
ditions. If brain imaging reveals SAH, it becomes imperative
to pursue vascular imaging to exclude a ruptured brain aneu-
rysm. However, ruptured aneurysms can bemissed on initial
angiography owing to factors such as vascular thrombosis or
obliteration by an adjacent hematoma,6,8 and approximately
3% to 8% of individuals harbor incidental unruptured brain
aneurysms,9making it difficult todetermine the source of the
SAH.For approximately 15%ofpatients, the sourceof the SAH
remains undetermined despite repeatedly undergoing angi-
ography (cryptogenic SAH [cSAH]); this group of patients has
variable outcomes depending on whether the patients have
nonperimesencephalicSAH,perimesencephalicSAH(blood lo-
calized to the basal cisterns), or evidence for recent SAH only
on cerebrospinal fluid examinations (negative for SAH on a
computed tomographic [CT] scan).10 Patients with aSAH or
nonperimesencephalic SAHhave ahigh risk for death anddis-
ability; hence, all patients with SAH are typically admitted to
the intensive care unit and repeatedly undergo angiography,
which rarely reveals the source of the SAH.8
These challenges suggest thatpatientswithSAHwho truly
have RCVS (ie, RCVS-SAH) may be subjected to the unneces-
sary risks of repeated imaging procedures (contrast reac-
tions, radiation exposure, and vessel dissections) and pro-
longed intensivecareunit stays.Our recentexperiencesuggests
that widely used SAH therapies such as induced hyperten-
sion, glucocorticoids, and intra-arterial vasodilator treat-
mentmaypose risks for patientswithRCVS-SAH.11,12 These is-
sues emphasize the importance of distinguishing RCVS-SAH
from aSAH and cSAH. In the present 2-center study, we com-
pared the clinical and imaging features of RCVS-SAH, aSAH,
and cSAH in order to identify clinical and radiological vari-
ables that can distinguish these conditions promptly after
presentation.
Methods
Patient Cohorts
The present study was approved by the institutional review
boards at Massachusetts General Hospital and University of
MassachusettsMemorialMedicalCenter.Thepatientswerede-
rived from 3 previously published cohorts for RCVS-SAH,12
aSAH,13,14 and cSAH.8
TheRCVS-SAHgroup comprised 38patients, including 35
patients with RCVS-SAH from a total of 84 consecutive RCVS
cases encountered by one of the authors (A.B.S) atMassachu-
setts General Hospital between 1998 and 2009 and 3 addi-
tional consecutive patients encountered by one of the au-
thors (S.M.) atUniversity ofMassachusettsMemorialMedical
Center from 2008 to 2009. All 38 patients had SAH detected
onCT scans of the head ormagnetic resonance imaging scans
of the brain and typical clinical-imaging features of RCVS as
published in the literature.1-5
The aSAH and cSAH cohorts were derived from a data-
base of 918 consecutive patients from 1995 to 2003 retrieved
from the Massachusetts General Hospital electronic medical
record system using the International Classification of Dis-
eases, NinthRevision, code430 for SAH.Themedical charts of
all patientswere reviewed.TheaSAHcohort comprised515pa-
tients with evidence of SAHdetected on CT scans of the head
orbyexaminationof cerebrospinal fluid samples andwithevi-
denceof at least 1 intracranial aneurysm following initial digi-
tal subtraction cerebral angiography (DSA), CT angiography
(CTA) of the head, ormagnetic resonance angiography (MRA)
of the head or a ruptured aneurysm identified during neuro-
surgery. The cSAHcohort comprised93patients forwhom ini-
tial laboratory and vascular imaging failed to reveal the un-
derlying cause (eg, aneurysm, vascularmalformation, arterial
dissection,RCVS,orvasculitis).Atourhospital, allpatientswith
SAH undergo 2 to 4 repeated vascular studies, including DSA
andCTA,8 before they receive the diagnosis of cSAH.Of these
93 patients, 48 had nonperimesencephalic cSAH, 36 had
perimesencephalic cSAH,and9hadCT-negativeSAH.Fourpa-
tients, allwithnonperimesencephalic SAH,proved tohave ce-
rebral aneurysms after repeatedlyundergoingDSA. Thesepa-
tientswere also included in theaSAHcohort;we justified their
inclusion in both cohorts because theywere clinically treated
as having cSAHprior to thediscovery of their aneurysms. The
remaining patients (n = 314) were excluded owing to SAH re-
sulting fromother causes (eg, arteriovenousmalformation or
trauma), late admission after day 14 of SAH (after the typical
vasospasmwindow), early death on days 0 to 4 of SAH (death
before the typical vasospasmwindow),moribund clinical sta-
tus (repeated vessel imaging or treatment of SAH was not at-
tempted), or incorrect coding for SAH.
Clinical Variables
Data definitions have been published8,12-14 and were consis-
tent across cohorts, allowing for comparison and analysis.
Medical history variables were obtained by reviewing the pa-
tients’ medical records; the variable was considered absent if
not listedaspositiveornotdocumentedasapriormedical con-
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dition. The term chronic headache disorder was used for pa-
tients reportingmigraines or other chronic headaches in their
medical history; the onset of headaches (eg, TCHs or sentinel
headaches) was not considered the onset of chronic head-
aches but rather a component of the acute presentation. Be-
cause the original RCVS data set did not include SAH Hunt-
Hess grades15 or Fisher groups,16 these variables were
retrospectively addedbyA.B.S. andS.M.ThemodifiedRankin
Scale scoreathospitaldischargewasderived fromphysical and
occupational therapists’ notes.
Radiological Variables
Every patient underwent DSA or CTA at admission. Most pa-
tients alsohad follow-upCTA,MRA,or serial transcranialDop-
pler ultrasonographic studies. AtMassachusettsGeneralHos-
pital, transcranial Doppler ultrasonographic studies are
performed for patientswith SAHat least oncedaily andwhen-
ever there is a change in theneurological examination. All pa-
tientswithRCVS-SAHunderwent 2 angiographic studies (79%
underwent DSA, 84% underwent CTA, and 63% underwent
MRA), except for 1patientwhoonlyunderwentDSA.Thepres-
ence of arterial narrowing was assessed, in order of prefer-
ence, by DSA, CTA, MRA, or transcranial Doppler ultrasono-
graphic study. The degree of arterial narrowingwas graded as
0 (none), 1 (<50%narrowing), or 2 (≥50%narrowing) basedon
visual inspection of angiographic studies (consensus by 2 re-
viewers, J.F. and A.B.S.) or using standard transcranial Dop-
plerultrasonographic studycriteria.17 Ifmultiple arterieswere
affected, the most severe grade of arterial narrowing was se-
lected. The laterality andnumber of vessels involvedwere re-
corded.The time tovasoconstrictionwasmeasured indays af-
ter onset of first TCH. All admission and follow-up brain
imaging studies were reviewed for the presence of infarction
or edema.
Statistical Analysis
Datawereanalyzedusing the t test, theχ2 test, or theFisher ex-
act test, as appropriate. To avoid overfitting due to the small
numberofpatientswithRCVS-SAH,wecreated2separatemul-
tivariable logistic regressionmodels forbaselineepidemiologi-
cal and acute clinical-radiological predictors. For the develop-
ment of the latter model, the presence of CT hypodensity was
omittedbecausehypodensitieswereconsideredpresent if they
developedat any timeduringhospitalizationandnot solely on
theCT scan at admission.Weomitted the variable “time to va-
soconstriction” in the multivariable analysis owing to a large
amount ofmissing data in the aSAH (343 of 515 patients [67%])
and cSAH (66 of 93 patients [71%]) cohorts. Odds ratios (ORs)
and95%CIswerecomputed.Pvaluesof less than .05werecon-
sidered to be statistically significant. Variables with P < .05 in
the univariate analysis were entered in a forward stepwise lo-
gistic regressionmodel. Goodness of fit was assessed by nega-
tive log likelihoods. The final model performance was re-
portedusing theC statistic. Thepreplanned logistic regression
model size was limited to 4 predictors, each due to the small
sample size of patients with RCVS-SAH. Owing to the baseline
inequalities of the groups for prior antidepressant use, we ad-
justed for this variable in the epidemiological model, thereby
allowing 5 variables in thismodel. Careful analysis of ORs and
95%CIsconfirmedthat themodelwasnotoverfitted.Firth’sbias
correction was used to handle the quasi-complete separation
ofdatapointsof theFishergroupvariable.18Analyseswereper-
formed using SAS version 9.3 (SAS Institute).
Results
Univariate Analysis
Baseline clinical characteristics are shown inTable 1. Patients
with RCVS-SAH were predominantly women and, on aver-
age, 12 years younger than thepatientswith aSAHand 11 years
younger than the patients with cSAH. Compared with both
aSAH and cSAH cohorts, more patients with RCVS-SAH had a
history of chronic headache disorder, depression/anxiety,
chronicobstructivepulmonarydisease (COPD), and illicit drug
and alcohol use. No colinearity was found between chronic
headache anddepression.A larger proportionof patientswith
RCVS-SAHusedantidepressants. PatientswithRCVS-SAHhad
less severe neurological presentations and lower Hunt-Hess
grades at presentation than did patients with aSAH or cSAH
(Table 1). Patients with RCVS-SAH had shorter lengths of stay
and better clinical outcomes at hospital discharge than pa-
tients with aSAH or cSAH.
Baseline radiological features are listed in Table 2. Pa-
tients with RCVS-SAHhad a higher incidence of CT hypoden-
sities (infarct or edema observed at admission or on early fol-
low-up scan) thandidpatientswith aSAHor cSAH.All patients
with RCVS-SAHhad subarachnoid blood located in the hemi-
spheric convexities (Fisher SAHgroup 2), as opposed to blood
in the sylvian fissure or basal cisterns commonly observed in
patients with aSAH or cSAH.
By definition, all patients with RCVS-SAH developed ce-
rebral arterial narrowing. In comparison, cerebral vasospasm
developed in 62% of patients with aSAH and in 29% of pa-
tients with cSAH at themedian time points of day 6 and day 7
after SAH, respectively.TheRCVS-SAHgroupshowedmore se-
vere cerebral artery narrowing andmore commonly hadmul-
tiple-artery involvement and bilateral abnormalities com-
pared with the aSAH and cSAH groups.
Multivariable Analysis
Predictors of RCVS-SAH vs aSAH
Multivariable logistic regression modeling of baseline epide-
miological variables, adjusting for prior antidepressant use,
showed that younger age, chronic headache disorder, history
of depression/anxiety, and COPD were independent predic-
tors of RCVS-SAH (model 1 in Table 3). The adjusted clinical-
radiological model (model 2 in Table 3) showed that a lower
Hunt-Hess grade, a lower Fisher SAH group, a higher number
of vessels affected, and thepresenceof bilateral vasoconstric-
tion (compared with unilateral or no vasoconstriction) inde-
pendently predicted RCVS-SAH.
Predictors of RCVS-SAH vs cSAH
Themultivariable logistic regressionmodel of baseline epide-
miological variables, adjusted for prior antidepressant use
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(model 1 inTable4), showed that younger age, female sex, his-
tory of hypertension, prior antidepressant use, and chronic
headache disorder were independent predictors of RCVS-
SAH. The adjusted acute clinical-radiologicalmodel (model 2
in Table 4) revealed that a lower Hunt-Hess grade, a lower
Fisher group, and the presence of bilateral vasoconstriction
(compared with unilateral or no vasoconstriction) indepen-
dently predicted RCVS-SAH.
Predictors of RCVS-SAH vs “Nonperimesencephalic” cSAH
Because all patients with RCVS-SAH had convexity SAH, we
performed an exploratory analysis restricted to the 48 pa-
tients with nonperimesencephalic cSAH. After adjusting for
prior antidepressant use, we found that the multivariable lo-
gistic regressionmodel of baseline epidemiological variables
identified similar predictors as in the nonrestricted cSAH
model: younger age (OR, 0.88 [95%CI, 0.83-0.94]), female sex
Table 1. Clinical Features
Clinical Variable
No. (%) P Value
RCVS-SAH
(n = 38)
aSAH
(n = 515)
cSAH
(n = 93)
RCVS-SAH
vs aSAH
RCVS-SAH
vs cSAH
Age, mean (SD), y 43 (12) 55 (14) 54 (14) <.001 <.001
Female sex 33 (87) 365 (71) 38 (41) .04 <.001
Medical history
Hypertension 17 (45) 176 (35) 23 (25) .21 .02
Diabetes mellitus 4 (11) 16 (3) 6 (7) .045 .47
Coronary artery disease 2 (5) 35 (7) 7 (8) .99 .99
Hypercholesterolemia 6 (16) 45 (9) 14 (15) .16 .99
Chronic headache disorder 18 (47) 39 (8) 5 (5) <.001 <.001
Depression/anxiety 17 (45) 41 (8) 7 (8) <.001 <.001
Drug abuse 8 (21) 24 (5) 2 (2) .001 <.001
Smoking 14 (37) 184 (36) 15 (16) .95 .01
Alcohol abuse 13 (34) 45 (9) 4 (4) <.001 <.001
COPD 12 (32) 43 (9) 5 (5) <.001 <.001
Prior antidepressant use 15 (39) 46 (9) 7 (8) <.001 <.001
Hunt-Hess grade
1 3 (8) 154 (30) 65 (70)
<.001 <.001
2 34 (89) 76 (15) 14 (15)
3 1 (3) 167 (33) 6 (7)
4 0 (0) 98 (19) 7 (8)
5 0 (0) 17 (3) 1 (1)
Median Hunt-Hess grade (IQR) 2 (2-2) 3 (1-3) 1 (1-2)
LOS, median (IQR), d 7 (3-9) 19 (12-26) 11 (8-17) <.001 <.001
mRS score, median (IQR) 0 (0-1) 2 (0-5) 1 (0-3) <.001 .02
Abbreviations: aSAH, aneurysmal
subarachnoid hemorrhage;
COPD, chronic obstructive pulmonary
disease; cSAH, cryptogenic
SAH; IQR, interquartile range;
LOS, length of stay; mRS, modified
Rankin Scale; RCVS-SAH, reversible
cerebral vasoconstriction syndrome
with SAH.
Table 2. Baseline Radiological Variables
Imaging Variable
No. (%) P Value
RCVS-SAH
(n = 38)
aSAH
(n = 515)
cSAH
(n = 93)
RCVS-SAH
vs aSAH
RCVS-SAH
vs cSAH
CT hypodensity 24 (63) 180 (35) 12 (13) <.001 <.001
Fisher SAH group
1 0 (0) 20 (4) 8 (9)
<.001 <.001
2 38 (100) 191 (38) 64 (69)
3 0 (0) 295 (58) 21 (23)
Median Fisher SAH group (IQR) 2 (2-2) 3 (2-3) 2 (2-2)
Occurrence of vasospasm 38 (100) 319 (62) 27 (29) <.001 <.001
Duration of vasospasm, median (IQR), d 1 (1-1) 6 (5-8) 7 (5-9) <.001 <.001
Narrowed arteries, median (IQR), No. 6 (6-9) 2 (0-4) 0 (0-1) <.001 <.001
Narrowing in ≥2 arteries 36 (95) 273 (53) 22 (24) <.001 <.001
Laterality of vessels affected
Unilateral 4 (11) 124 (24) 11 (12)
<.001 <.001
Bilateral 34 (89) 187 (36) 17 (18)
Degree of narrowing,a median (IQR) 2 (2-2) 2 (1-2) 1 (1-1) .05 <.001
Abbreviations: aSAH, aneurysmal
subarachnoid hemorrhage;
cSAH, cryptogenic SAH;
CT, computerized tomographic;
CTA, CT angiogram; IQR, interquartile
range; RCVS, reversible cerebral
vasoconstriction syndrome.
a Severity of arterial narrowing: 0, no
arterial narrowing; 1, <50%
narrowing; and 2,50% narrowing.
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(OR, 9.9 [95%CI, 2.0-47.8]), history of hypertension (OR, 10.3
[95% CI, 1.9-55.4]), and history of chronic headache disorder
(OR, 5.5 [95% CI, 1.2-24.6]). The adjusted acute clinical-
radiological model showed that bilateral arterial narrowing
(comparedwithunilateralornoarterialnarrowing;OR,9.1 [95%
CI, 3.5-23.8]) was the only predictor of RCVS-SAH.
Discussion
In the present study, we identified epidemiological and
clinical-radiological predictors, obtained at the time of
admission and before disease evolution, which can distin-
guish RCVS-SAH from 2 important mimics. Our results are
clinically significant in that enhanced bedside diagnostic
accuracy may effect the length of stay in the neurological
intensive care unit or hospital, may reduce the number of
diagnostic tests, and may improve the management of
patients presenting with SAH, although we did not examine
this in our study. Clinicians may use these data to distin-
guish RCVS-SAH, a usually benign entity, from aSAH, which
is a common and often life-threatening cause of stroke in
young adults. Furthermore, when the initial angiographic
studies do not reveal a ruptured brain aneurysm or other
sources of SAH, these predictors can be used to distinguish
RCVS-SAH from cSAH, which is often a major diagnostic
dilemma. Most of the RCVS-SAH predictors identified in our
study are not surprising and match the typical RCVS
profile1-5; indeed, the experienced clinician may find the
results all too obvious. However, to date, diagnosis has been
based on empirical grounds, and for the first time, we pro-
vide data showing that RCVS is a distinct entity and that
RCVS-SAH is very different from aSAH and cSAH.
Some authors have questioned whether RCVS (particu-
larly RCVS-SAH) is different from aSAH or cSAH (ie, whether
minor, often undetectable amounts of subarachnoid blood
can trigger the vasoconstriction observed in RCVS). We have
previously highlighted several differences between these
conditions19; in this present study, we provide evidence that
RCVS-SAH differs from aSAH and cSAH in many respects,
including mean age of patients, risk factors identified from
the medical history and medications, clinical presentation,
brain imaging, and cerebral angiographic findings. Our
results suggest that the diffuse, multifocal, prolonged vaso-
constriction in RCVS is unrelated to the presence or location
of subarachnoid blood. We believe that RCVS-associated
SAH, which is usually restricted to 1 to 2 sulcal spaces, is
unlikely to cause diffuse, multifocal vasoconstriction but,
instead, likely results from dynamic caliber changes affect-
ing cortical surface vessels. The vasoconstriction in RCVS
may be dependent on the activity and sensitivity of vascular
receptors, which can lead to a more systemic effect on all
brain vessels,1 as opposed to being dependent on the vaso-
spasm induced by local clot lysis, as has been suggested
in aSAH.20 Further studies are warranted to understand
the pathophysiology of vasoconstriction and the cause of
the convexity of SAH in RCVS.
Although the differences are striking, we emphasize,
based on our clinical experience, that the most important
diagnostic feature for RCVS is the presence of recurrent
TCHs, which is a feature that was not captured in this retro-
spective study. The presence of TCHs is the clinical hallmark
of aSAH; however, more than 80% of patients with aSAH
develop only a single TCH,6 and less than 20% of patients
with cSAH develop sentinel headaches,21 whereas 82% to
100% of patients with RCVS develop 3 to 4 recurrent TCHs in
the first few days.22 Indeed, although TCH has a broad differ-
ential diagnosis, recurrent TCHs are the sine qua non of
RCVS; including this feature with the other predictors identi-
fied in our study would easily distinguish RCVS-SAH from
aSAH or cSAH.
Reversible cerebral vasoconstriction syndrome is a com-
mon cause of nontraumatic convexal SAH. In our experi-
ence, 50% of patients with RCVS develop convexal SAH,12
Table 3. Multivariate Logistic RegressionModels Differentiating
RCVS-SAH From aSAH
Variable OR (95% CI) C Statistic
Model 1a
Age 0.93 (0.90-0.96)
0.90
Chronic headache disorder 9.4 (3.9-22.5)
History of depression 5.9 (1.9-18.0)
COPD 7.6 (2.9-20.1)
Prior antidepressant use 2.4 (0.8-7.4)
Model 2b
Hunt-Hess grade 0.4 (0.2-0.7)
0.94
Fisher group 0.1 (0.05-0.3)
No. of affected arteries 1.4 (1.2-1.6)
Laterality of affected arteries 5.7 (2.1-15.0)
Abbreviations: aSAH, aneurysmal subarachnoid hemorrhage; COPD, chronic
obstructive pulmonary disease; OR, odds ratio; RCVS, reversible cerebral
vasoconstriction syndrome.
a Baseline epidemiological variables, adjusted for prior antidepressant use.
bAcute clinical and radiological variables.
Table 4. Multivariate Logistic RegressionModels Differentiating
RCVS-SAH From cSAH
Variable OR (95% CI) C Statistic
Model 1a
Age 0.87 (0.82-0.93)
0.91
Female sex 19.1 (3.8-94.9)
History of hypertension 17.2 (3.3-88.9)
Chronic headache disorder 8.7 (2.1-36.9)
Prior antidepressant use 6.8 (1.3-36.5)
Model 2b
Hunt-Hess grade 3.1 (1.1-8.8)
0.97Fisher group 0.01 (<0.001-0.11)
Laterality of affected arteries 31.3 (8.9-110.0)
Abbreviations: aSAH, aneurysmal subarachnoid hemorrhage; OR, odds ratio;
RCVS, reversible cerebral vasoconstriction syndrome.
a Baseline epidemiological variables, adjusted for prior antidepressant use.
bAcute clinical and radiological variables; Firth’s bias-correction18 was used to
handle the quasi-complete separation of data points of the Fisher group
variable.
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and a prospective study2 of RCVS found a 30% incidence of
convexal SAH. In a recent study23 of 29 patients with con-
vexal SAH, it was found that 16 of those patients who were
60 years of age or younger had RCVS. Clinically, it is impor-
tant to distinguish RCVS from other causes of convexal hem-
orrhage. Hence, we performed an exploratory analysis com-
paring the group of patients with RCVS-SAH with the
subgroup of patients with cSAH who had nonperimesence-
phalic SAH. Despite the small number of patients in each
group, we identified independent predictors that can distin-
guish these conditions. We anticipate that these results may
enhance the clinical decision-making process with regard to
patients presenting with convexal SAH.
The association between COPD and RCVS-SAH was
unanticipated and requires confirmation. It is conceivable
that patients with COPD have underlying risk factors for
RCVS, such as cerebrospinal fluid leakage with hypotension
resulting from chronic cough, chronic exposure to deconges-
tant (vasoconstrictive) medications, or exposure to glucocor-
ticoids, which have been associated with worse outcomes in
RCVS.12 Smoking is an unlikely contributing factor because
we found no difference in the proportion of smokers among
the cohorts, and no colinearity between smoking and COPD.
Because chronic headaches and depression often occur con-
currently in clinical practice, we tested for and ruled out
colinearity, confirming that they are independent predictors.
We found that prior antidepressant use distinguished
RCVS-SAH from cSAH and tended to distinguish it from
cSAH. Antidepressants induce vasoconstriction from sero-
tonergic and sympathomimetic effects, and have previously
been associated with RCVS,1,12,24 as well as symptomatic
vasospasms after aSAH.14 We emphasize that the CIs for
most predictors were fairly wide, likely owing to small
patient numbers, and suggest that these predictors should
be used in combination rather than in isolation. Future stud-
ies should seek to develop and validate a diagnostic scoring
system using these variables.
Although we analyzed one of the largest cohorts of pa-
tientswithRCVS-SAHandasubstantialnumberofpatientswith
aSAH or cSAH, we acknowledge that the sample sizes are still
small and that biasesmay exist owing to the retrospective na-
ture of the study and data collection spanning several years.
Our aSAH data set did not contain patients with SAH from ar-
teriovenous malformations, dural arteriovenous fistulas, or
other vascular lesions. The strengthsof our study lie in theuse
of uniform data definitions, the level of certainty in grading
vasoconstriction (because all patients in all 3 cohorts under-
went CTA or DSA, both of which are superior to MRA or TCD
for assessing vasoconstriction),25 and themanagement of pa-
tients with aSAH or cSAH consistent with publishedmanage-
ment guidelines.26
In summary, we envision that the epidemiological and
clinical-imaging predictors identified in our study may en-
able a prompt and accurate diagnosis, and have an effect on
patientmanagement. Future studies shouldevaluatewhether
the use of these predictors, combined with the growing rec-
ognition of RCVS and accumulating clinical experience, will
ultimately improve bedside diagnosis, reduce the number of
unnecessary tests, and decrease the length of hospitaliza-
tion. Diagnostic biomarker studies are unlikely to add value
totheseresults;however, futurebiomarkerandmolecularstud-
ies may still be helpful for understanding themechanisms of
cerebral vasoconstriction or vasospasm and for developing
novel treatments.
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